Home › Companies › ARBUTUS BIOPHARMA CORP. › 2023-2024

ARBUTUS BIOPHARMA CORP. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and ARBUTUS BIOPHARMA CORP.’s Form 8-K, filed 2024-05-28 (Item 5.07 on EDGAR). Page generated 04 October 2026.

10Reported items
113Asset managers
1,201Fund votes
2024-05-22Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ARBUTUS BIOPHARMA CORP. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ARBUTUS BIOPHARMA CORP.

These tallies are ARBUTUS BIOPHARMA CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-05-28 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ARBUTUS BIOPHARMA CORP. — official shareholder meeting results, meeting held 2024-05-22
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Frank Torti, M.D.	116,514,685	--	--	6,089,738	24,915,140	Majority: yes
Elect Director: Michael J. McElhaugh	110,465,378	--	--	12,139,045	24,915,140	Majority: yes
Elect Director: Daniel Burgess	110,133,889	--	--	12,470,534	24,915,140	Majority: yes
Elect Director: Richard C. Henriques	109,654,719	--	--	12,949,704	24,915,140	Majority: yes
Elect Director: Keith Manchester, M.D.	105,954,077	--	--	16,650,346	24,915,140	Majority: yes
Elect Director: James Meyers	110,186,534	--	--	12,417,889	24,915,140	Majority: yes
Elect Director: Melissa V. Rewolinski, Ph.D.	111,055,063	--	--	11,549,360	24,915,140	Majority: yes

Source: ARBUTUS BIOPHARMA CORP., Form 8-K, filed with the SEC on 2024-05-28 — read the filing on EDGAR.

How asset managers voted at the ARBUTUS BIOPHARMA CORP. 2023-2024 meeting

Each item below shows how the 113 asset managers that disclosed a ARBUTUS BIOPHARMA CORP. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ARBUTUS BIOPHARMA CORP.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement/Circular; and

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

82% fund support · no official result

FOR 64%14%ABSTAIN 21%

The 110 asset managers below cast 82% of the shares they voted on this item FOR (35,942,988 for, 7,795,814 against).

FOR: 35,942,988 (64.4%)AGAINST: 7,795,814 (14.0%)ABSTAIN: 11,982,343 (21.5%)SPLIT: 64,726 (0.1%)

Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in ” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset manager	For	Against	Abstain	Vote
Morgan Stanley	5,603	0	11,622,103	Abstain
BlackRock	10,383,424	0	0	For
Two Seas Capital LP	0	7,463,977	0	Against
Vanguard	5,950,418	0	0	For
Woodline Partners LP	3,249,673	0	0	For
Hudson Bay Capital Management LP	3,028,235	0	0	For
Fidelity	1,678,312	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,641,275	0	0	For
State Street	1,507,291	0	0	For
Centiva Capital, LP	1,322,827	0	0	For
Citadel	1,083,522	0	0	For
Northern Trust	1,005,577	233	0	For
Corbin Capital Partners, L.P.	847,231	0	0	For
Charles Schwab	678,430	0	0	For
Equitable	316,121	0	352,297	Abstain
Wellington	381,140	0	0	For
BOOTHBAY FUND MANAGEMENT, LLC	352,255	0	0	For
MELLON INVESTMENTS Corp	298,260	0	0	For
KENNEDY CAPITAL MANAGEMENT LLC	285,924	0	0	For
American Century	0	250,850	0	Against
QUANTITATIVE MASTER SERIES LLC	236,161	0	0	For
PARAMETRIC PORTFOLIO ASSOCIATES LLC	185,721	0	0	For
John Hancock	106,264	0	0	For
Lincoln Financial	103,000	0	0	For
AllianceBernstein	96,040	0	0	For

Showing the 25 largest of 110 asset managers. See all 110 in the interactive database.

2. To approve an amendment to the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended, to (a) increase the aggregate number of common shares authorized for issuance thereunder by 9,500,000 common shares and (b) increase the aggregate number of common shares that may be issued pursuant to incentive stock options granted thereunder by 9,500,000 common shares

COMPENSATION

Combines 3 wordings of this item as funds reported it.

99.2% fund support · no official result

FOR 99%

The 35 asset managers below cast 99.2% of the shares they voted on this item FOR (18,274,527 for, 136,685 against).

FOR: 18,274,527 (98.9%)AGAINST: 136,685 (0.7%)SPLIT: 64,726 (0.4%)

Largest asset managers voting on “To approve an amendment to the Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplem” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset manager	For	Against	Vote
Vanguard	5,797,952	0	For
BlackRock	5,441,167	0	For
Morgan Stanley	3,557,535	0	For
Fidelity	1,582,554	0	For
Equitable	668,418	0	For
Charles Schwab	339,215	0	For
QUANTITATIVE MASTER SERIES LLC	236,161	0	For
American Century	0	125,425	Against
Lincoln Financial	103,000	0	For
Saba Capital Income & Opportunities Fund	0	0	Split
Northern Trust	63,216	0	For
John Hancock	53,132	0	For
Pacific Life	50,453	0	For
Voya	44,905	0	For
Amplify ETF Trust	43,299	0	For
Brighthouse	41,612	0	For
ProShares	32,536	0	For
Bridge Builder Trust	30,581	0	For
Nationwide	28,894	0	For
Principal Exchange-Traded Funds	25,400	0	For
Invesco	19,699	0	For
DWS	19,583	0	For
AIG/SunAmerica	18,384	0	For
SEI	16,700	0	For
Principal	14,684	0	For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

3. To approve the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

AUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.6%

The 35 asset managers below cast 100% of the shares they voted on this item FOR (18,411,212 for, 0 against).

FOR: 18,411,212 (99.6%)SPLIT: 64,726 (0.4%)

Largest asset managers voting on “To approve the appointment of Ernst & Young LLP as our independent registered public accounting firm for the f” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset manager	For	Vote
Vanguard	5,797,952	For
BlackRock	5,441,167	For
Morgan Stanley	3,557,535	For
Fidelity	1,582,554	For
Equitable	668,418	For
Charles Schwab	339,215	For
QUANTITATIVE MASTER SERIES LLC	236,161	For
American Century	125,425	For
Lincoln Financial	103,000	For
Saba Capital Income & Opportunities Fund	0	Split
Northern Trust	63,216	For
John Hancock	53,132	For
Pacific Life	50,453	For
Voya	44,905	For
Amplify ETF Trust	43,299	For
Brighthouse	41,612	For
ProShares	32,536	For
Bridge Builder Trust	30,581	For
Nationwide	28,894	For
Principal Exchange-Traded Funds	25,400	For
Invesco	19,699	For
DWS	19,583	For
AIG/SunAmerica	18,384	For
SEI	16,700	For
Principal	14,684	For

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

4. To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Daniel Burgess

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%

FOR: 110,133,889WITHHELD: 12,470,534

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Daniel Burgess”): 110,133,889 for, 12,470,534 withheld, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 188,717,409 outstanding shares: 58% for, 7% withheld (65% of the company cast a for/withheld vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (18,194,797 for, 0 against).

FOR 99%

FOR: 18,194,797 (98.8%)ABSTAIN: 216,415 (1.2%)

Largest asset managers voting on “To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annua” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	5,797,952	0	For
BlackRock	5,441,167	0	For
Morgan Stanley	3,557,535	0	For
Fidelity	1,498,193	84,361	For
Equitable	572,378	96,040	For
Charles Schwab	339,215	0	For
QUANTITATIVE MASTER SERIES LLC	236,161	0	For
American Century	125,425	0	For
Lincoln Financial	103,000	0	For
Northern Trust	63,216	0	For
John Hancock	53,132	0	For
Pacific Life	50,453	0	For
Voya	44,905	0	For
Amplify ETF Trust	43,299	0	For
Brighthouse	41,612	0	For
ProShares	32,536	0	For
Bridge Builder Trust	30,581	0	For
Nationwide	28,894	0	For
Principal Exchange-Traded Funds	25,400	0	For
Invesco	0	19,699	Abstain
DWS	19,583	0	For
AIG/SunAmerica	18,384	0	For
SEI	16,700	0	For
Principal	14,684	0	For
Federated Hermes	11,033	0	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

5. To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Frank Torti, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 116,514,685WITHHELD: 6,089,738

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Frank Torti, M.D.”): 116,514,685 for, 6,089,738 withheld, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 188,717,409 outstanding shares: 62% for, 3% withheld (65% of the company cast a for/withheld vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (18,402,088 for, 0 against).

FOR 99.9%

FOR: 18,402,088 (100.0%)ABSTAIN: 9,124 (0.0%)

Largest asset managers voting on “To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annua” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset manager	For	Vote
Vanguard	5,797,952	For
BlackRock	5,441,167	For
Morgan Stanley	3,557,535	For
Fidelity	1,582,554	For
Equitable	668,418	For
Charles Schwab	339,215	For
QUANTITATIVE MASTER SERIES LLC	236,161	For
American Century	125,425	For
Lincoln Financial	103,000	For
Northern Trust	63,216	For
John Hancock	53,132	For
Pacific Life	50,453	For
Voya	44,905	For
Amplify ETF Trust	43,299	For
Brighthouse	41,612	For
ProShares	32,536	For
Bridge Builder Trust	30,581	For
Nationwide	28,894	For
Principal Exchange-Traded Funds	25,400	For
Invesco	19,699	For
DWS	19,583	For
AIG/SunAmerica	18,384	For
SEI	16,700	For
Principal	14,684	For
Federated Hermes	11,033	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

6. To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: James Meyers

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%

FOR: 110,186,534WITHHELD: 12,417,889

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: James Meyers”): 110,186,534 for, 12,417,889 withheld, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 188,717,409 outstanding shares: 58% for, 7% withheld (65% of the company cast a for/withheld vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (18,214,496 for, 0 against).

FOR 99%

FOR: 18,214,496 (98.9%)ABSTAIN: 196,716 (1.1%)

Largest asset managers voting on “To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annua” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	5,797,952	0	For
BlackRock	5,441,167	0	For
Morgan Stanley	3,557,535	0	For
Fidelity	1,498,193	84,361	For
Equitable	572,378	96,040	For
Charles Schwab	339,215	0	For
QUANTITATIVE MASTER SERIES LLC	236,161	0	For
American Century	125,425	0	For
Lincoln Financial	103,000	0	For
Northern Trust	63,216	0	For
John Hancock	53,132	0	For
Pacific Life	50,453	0	For
Voya	44,905	0	For
Amplify ETF Trust	43,299	0	For
Brighthouse	41,612	0	For
ProShares	32,536	0	For
Bridge Builder Trust	30,581	0	For
Nationwide	28,894	0	For
Principal Exchange-Traded Funds	25,400	0	For
Invesco	19,699	0	For
DWS	19,583	0	For
AIG/SunAmerica	18,384	0	For
SEI	16,700	0	For
Principal	14,684	0	For
Federated Hermes	11,033	0	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

7. To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Keith Manchester, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%14%

FOR: 105,954,077WITHHELD: 16,650,346

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Keith Manchester, M.D.”): 105,954,077 for, 16,650,346 withheld, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 188,717,409 outstanding shares: 56% for, 9% withheld (65% of the company cast a for/withheld vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (17,391,946 for, 0 against).

FOR 94%

FOR: 17,391,946 (94.5%)ABSTAIN: 1,019,266 (5.5%)

Largest asset managers voting on “To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annua” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	5,797,952	0	For
BlackRock	5,441,167	0	For
Morgan Stanley	3,557,535	0	For
Fidelity	1,498,193	84,361	For
Equitable	572,378	96,040	For
Charles Schwab	0	339,215	Abstain
QUANTITATIVE MASTER SERIES LLC	236,161	0	For
American Century	125,425	0	For
Lincoln Financial	0	103,000	Abstain
Northern Trust	0	63,216	Abstain
John Hancock	0	53,132	Abstain
Pacific Life	50,453	0	For
Voya	0	44,905	Abstain
Amplify ETF Trust	43,299	0	For
Brighthouse	0	41,612	Abstain
ProShares	0	32,536	Abstain
Bridge Builder Trust	30,581	0	For
Nationwide	0	28,894	Abstain
Principal Exchange-Traded Funds	0	25,400	Abstain
Invesco	19,699	0	For
DWS	0	19,583	Abstain
AIG/SunAmerica	0	18,384	Abstain
SEI	0	16,700	Abstain
Principal	0	14,684	Abstain
Federated Hermes	11,033	0	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

8. To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Melissa V. Rewolinski, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 111,055,063WITHHELD: 11,549,360

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Melissa V. Rewolinski, Ph.D.”): 111,055,063 for, 11,549,360 withheld, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 188,717,409 outstanding shares: 59% for, 6% withheld (65% of the company cast a for/withheld vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (18,411,212 for, 0 against).

FOR 100%

FOR: 18,411,212 (100.0%)

Largest asset managers voting on “To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annua” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset manager	For	Vote
Vanguard	5,797,952	For
BlackRock	5,441,167	For
Morgan Stanley	3,557,535	For
Fidelity	1,582,554	For
Equitable	668,418	For
Charles Schwab	339,215	For
QUANTITATIVE MASTER SERIES LLC	236,161	For
American Century	125,425	For
Lincoln Financial	103,000	For
Northern Trust	63,216	For
John Hancock	53,132	For
Pacific Life	50,453	For
Voya	44,905	For
Amplify ETF Trust	43,299	For
Brighthouse	41,612	For
ProShares	32,536	For
Bridge Builder Trust	30,581	For
Nationwide	28,894	For
Principal Exchange-Traded Funds	25,400	For
Invesco	19,699	For
DWS	19,583	For
AIG/SunAmerica	18,384	For
SEI	16,700	For
Principal	14,684	For
Federated Hermes	11,033	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

9. To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Michael J. McElhaugh

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%

FOR: 110,465,378WITHHELD: 12,139,045

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Michael J. McElhaugh”): 110,465,378 for, 12,139,045 withheld, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 188,717,409 outstanding shares: 59% for, 6% withheld (65% of the company cast a for/withheld vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (18,411,212 for, 0 against).

FOR 100%

FOR: 18,411,212 (100.0%)

Largest asset managers voting on “To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annua” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset manager	For	Vote
Vanguard	5,797,952	For
BlackRock	5,441,167	For
Morgan Stanley	3,557,535	For
Fidelity	1,582,554	For
Equitable	668,418	For
Charles Schwab	339,215	For
QUANTITATIVE MASTER SERIES LLC	236,161	For
American Century	125,425	For
Lincoln Financial	103,000	For
Northern Trust	63,216	For
John Hancock	53,132	For
Pacific Life	50,453	For
Voya	44,905	For
Amplify ETF Trust	43,299	For
Brighthouse	41,612	For
ProShares	32,536	For
Bridge Builder Trust	30,581	For
Nationwide	28,894	For
Principal Exchange-Traded Funds	25,400	For
Invesco	19,699	For
DWS	19,583	For
AIG/SunAmerica	18,384	For
SEI	16,700	For
Principal	14,684	For
Federated Hermes	11,033	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

10. To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Richard C. Henriques

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 109,654,719WITHHELD: 12,949,704

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Richard C. Henriques”): 109,654,719 for, 12,949,704 withheld, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 188,717,409 outstanding shares: 58% for, 7% withheld (65% of the company cast a for/withheld vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (18,411,212 for, 0 against).

FOR 100%

FOR: 18,411,212 (100.0%)

Largest asset managers voting on “To elect seven (7) director nominees named in the Proxy Statement/Circular, each to serve until the 2025 Annua” at ARBUTUS BIOPHARMA CORP., 2023-2024
Asset manager	For	Vote
Vanguard	5,797,952	For
BlackRock	5,441,167	For
Morgan Stanley	3,557,535	For
Fidelity	1,582,554	For
Equitable	668,418	For
Charles Schwab	339,215	For
QUANTITATIVE MASTER SERIES LLC	236,161	For
American Century	125,425	For
Lincoln Financial	103,000	For
Northern Trust	63,216	For
John Hancock	53,132	For
Pacific Life	50,453	For
Voya	44,905	For
Amplify ETF Trust	43,299	For
Brighthouse	41,612	For
ProShares	32,536	For
Bridge Builder Trust	30,581	For
Nationwide	28,894	For
Principal Exchange-Traded Funds	25,400	For
Invesco	19,699	For
DWS	19,583	For
AIG/SunAmerica	18,384	For
SEI	16,700	For
Principal	14,684	For
Federated Hermes	11,033	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

Largest ARBUTUS BIOPHARMA CORP. shareholders voting in 2023-2024

Ranked by the number of ARBUTUS BIOPHARMA CORP. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 188,717,409 shares outstanding at the time of that meeting.

Top ARBUTUS BIOPHARMA CORP. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	Morgan Stanley	6.16%
2	BlackRock	5.50%
3	Two Seas Capital LP	3.96%
4	Vanguard	3.15%
5	Woodline Partners LP	1.72%
6	Hudson Bay Capital Management LP	1.60%
7	Fidelity	0.89%
8	GEODE CAPITAL MANAGEMENT, LLC	0.87%
9	State Street	0.80%
10	Centiva Capital, LP	0.70%

Reported ARBUTUS BIOPHARMA CORP. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ARBUTUS BIOPHARMA CORP. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Roivant	20.58%	DEF14A
Morgan Stanley	12.96%	13F
Whitefort Capital Management, LP	6.99%	13G
Blackrock, Inc.	5.51%	DEF14A
Two Seas Capital LP	4.79%	DEF14A
Vanguard Group	4.76%	13F
Michael J. Sofia, Ph.D.	1.50%	DEF14A
State Street	1.38%	13F
Michael J. McElhaugh	1.18%	DEF14A
Citadel Advisors	1.16%	13F

Percentages above are of 188,717,409 shares outstanding, as reported by ARBUTUS BIOPHARMA CORP. on its Form 10-Q dated 2024-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARBUTUS BIOPHARMA CORP.’s 10-Q dated 2024-04-30. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At ARBUTUS BIOPHARMA CORP.'s shareholder meeting held 2024-05-22, in the 2023-2024 proxy season, 113 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,201 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. ARBUTUS BIOPHARMA CORP.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — the reporting funds cast 82% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

ARBUTUS BIOPHARMA CORP. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.